JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

TransMedics Group Inc

Închisă

SectorSănătate

130.6 2.1

Rezumat

Modificarea prețului

24h

Curent

Minim

128.42

Maxim

134.02

Indicatori cheie

By Trading Economics

Venit

9.2M

35M

Vânzări

14M

157M

P/E

Medie Sector

59.064

37.461

Marjă de profit

22.181

Angajați

728

EBITDA

10M

46M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+12.09% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

527M

4.1B

Deschiderea anterioară

128.5

Închiderea anterioară

130.6

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

TransMedics Group Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparație

Modificare preț

TransMedics Group Inc Așteptări

Obiectiv de preț

By TipRanks

12.09% sus

Prognoză pe 12 luni

Medie 144.5 USD  12.09%

Maxim 170 USD

Minim 115 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTransMedics Group Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

9

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

92.43 / 94.18Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat